Health Care & Life Sciences » Pharmaceuticals | Strongbridge Biopharma PLC

Strongbridge Biopharma PLC | Ownership

Companies that own Strongbridge Biopharma PLC

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Caxton Corp.
6,294,829
13.48%
896,795
34.79%
08/08/2018
Lyon Street Capital LLC
4,565,633
9.77%
1,383,484
7.87%
06/30/2018
Broadfin Capital LLC
2,340,649
5.01%
-453,103
1.77%
06/30/2018
Armistice Capital LLC
2,158,000
4.62%
-1,214,000
0.9%
06/30/2018
Opaleye Management, Inc.
1,830,000
3.92%
240,000
2.54%
06/30/2018
Park West Asset Management LLC
1,081,800
2.31%
300,000
0.24%
06/30/2018
Harvest Capital Strategies LLC
967,243
2.06%
142,243
1.06%
06/30/2018
Sphera Funds Management Ltd.
673,996
1.44%
673,996
0.54%
06/30/2018
Millennium Management LLC
662,419
1.42%
524,539
0.01%
06/30/2018
Granite Point Capital Management LP
567,895
1.22%
0
1.25%
06/30/2018

About Strongbridge Biopharma

View Profile
Address
900 Northbrook Drive
Lower Southampton Pennsylvania 19053
United States
Employees -
Website http://www.strongbridgebio.com
Updated 07/08/2019
Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded on May 26, 2015 and is headquartered in Lower Southampton, PA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.